Skip to main content

Table 2 CircRNAs as diagnostic and prognostic biomarkers in GC

From: Biogenesis, functions and clinical significance of circRNAs in gastric cancer

Name Dysregulation Function Sensitivity Specificity Cut-off value (ΔCt) AUC Clinicopathological association Ref.
circPVT1 up-regulated Independent prognostic indicator; 0.605 Tumor stage and overall survival time [75]
hsa_circ_0014717 downregulated Diagnostic biomarker 59.38% 81.25% 12.14 0.696 Tumor stage, distal metastasis, CEA, and CA19–9 [92]
circLARP4 downregulated Independent prognostic indicator 67.4% 67.6% 20.37 0.64 Tumor size and lymphatic metastasis [96]
circ-KIAA1244 downregulated Independent prognostic indicator 77.42% 68.00% 1.443 0.748 TNM stage, lymphatic metastasis and overall survival time [99]
hsa_circ_0000467 up-regulated Independent prognostic factor; potential target 70.5% 64.8% 0.799 Lymphatic invasion, and TNM stage [100]
hsa_circ_0000190 downregulated Diagnosis biomarker 72.1% 68.3% 6.83 0.75 Tumor size, lymphatic metastasis, distal metastasis, TNM stage and CA19–9 [101]
hsa_circ_002059 downregulated Diagnosis biomarker 81% 62% 12.9 0.73 TNM stage, distal metastasis, gender and age [102]
hsa_circ_0000181 downregulated Diagnosis biomarker 20.6% 99% 7.27 0.582 Differentiation and CEA (plasma) [103]
85.2% 53.9% 9.4 0.756 Tumor diameter, lymphatic metastasis, distal metastasis and CA19–9 (tissue)
hsa_circ_0000096 downregulated Diagnosis biomarker 12.9 0.82 Gender, invasion and TNM stage [104]
hsa_circ_0003159 downregulated Diagnosis biomarker 85.2% 56.5% 12.31 0.75 Gender, TNM stage and distal metastasis [105]
circPSMC3 downregulated Diagnosis and prognosis biomarker 85.85% 95.24% 9.965 0.933 TNM stage and lymphatic metastasis [95]
hsa_circ_0000745 downregulated Diagnosis biomarker 85.5% 45% 0.683 TNM stage (plasma) and tumor differentiation (tissue) [106]
hsa_circ_0006633 downregulated Diagnosis biomarker 60% 81% 8.17 0.741 Distal metastasis and CEA [107]
hsa_circ_0001649 downregulated Independent prognostic indicator and diagnosis biomarker 71.1% 81.6% 0.227 0.834 Tumor differentiation [108]
hsa_circ_0001895 downregulated Prognosis biomarker 67.8% 85.7% 9.53 0.792 Cell differentiation, Borrmann type, and CEA [109]
has_circ_0074362 downregulated Diagnosis biomarker 84.3% 36.2% 12.17 0.63 Lymphatic metastasis and CA19–9 [110]
hsa_circ_102958 up-regulated Diagnosis biomarker 61% 86% 0.74 TNM stage [111]
has_circ_0066444 up-regulated Diagnosis biomarker 70.75% 68.87% 0.733 Lymph metastasis [112]
  1. AUC Area under the curve, CA19–9 Carbohydrate antigen 19–9, CEA Carcinoembryonic antigen